Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page
- ChecktodayChange DetectedThe site footer now identifies the ClinicalTrials.gov version as v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA sitewide NIH notice about terminology changes during a federal transition no longer appears at the top of the page.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the study record remains unavailable and displays a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.